D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)

Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and a...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Maher, T M, Bareille, P, Costa, M J, Fahy, W A, Harrison, S A, Holman, B F, Lukey, P, Man, Y, Saunders, P, Simpson, J K, Toshner, R, Woodcock, H V, Yang, S, Marshall, R P
Format: Article
Language:English
Subjects:
Pulmonary fibrosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and again during the course of the dosing period.
ISSN:1073-449X
1535-4970